Sunday, 8 August 2010

Geodon


Geodon is a brand name of ziprasidone, approved by the FDA in the following formulation(s):


GEODON (ziprasidone hydrochloride - capsule; oral)



  • Manufacturer: PFIZER

    Approval date: February 5, 2001

    Strength(s): EQ 20MG BASE [RLD], EQ 40MG BASE, EQ 60MG BASE, EQ 80MG BASE

GEODON (ziprasidone hydrochloride - suspension; oral)



  • Manufacturer: PFIZER INC

    Approval date: March 29, 2006

    Strength(s): EQ 10MG BASE/ML [RLD]

GEODON (ziprasidone mesylate - injectable; intramuscular)



  • Manufacturer: PFIZER

    Approval date: June 21, 2002

    Strength(s): EQ 20MG BASE/ML [RLD]

Has a generic version of Geodon been approved?


No. There is currently no therapeutically equivalent version of Geodon available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Geodon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Aryl piperazinyl-(C.sub.2 or C.sub.4) alkylene heterocyclic compounds having neuroleptic activity
    Patent 4,831,031
    Issued: May 16, 1989
    Inventor(s): Lowe, III; John A. & Nagel; Arthur A.
    Assignee(s): Pfizer Inc.
    Arylpiperazinyl-ethyl(or butyl)-heterocyclic compounds and their pharmaceutically acceptable acid addition salts are neuroleptic agents. They are useful in the treatment of psychotic disorders.
    Patent expiration dates:

    • March 2, 2012
      ✓ 
      Patent use: TREATMENT OF NEUROLEPTIC DISEASES
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dih ydro-2H-indol-2-one-hydrochloride
    Patent 5,312,925
    Issued: May 17, 1994
    Inventor(s): Allen; Douglas J. M. & Busch; Frank R. & DiRoma; Sabeto A. & Godek; Dennis M.
    Assignee(s): Pfizer Inc.
    The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indole-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.
    Patent expiration dates:

    • September 1, 2012
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • September 1, 2012
      ✓ 
      Patent use: TREATMENT OF NEUROLEPTIC DISEASES
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
    Patent 6,110,918
    Issued: August 29, 2000
    Inventor(s): Busch; Frank R. & Rose; Carol A.
    Assignee(s): Pfizer Inc
    Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use as Dopamine D2 Antagonist The invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one ("ziprasidone mesylate trihydrate"), to pharmaceutical compositions containing ziprasidone mesylate trihydrate, and to methods of administering ziprasidone mesylate trihydrate to treat psychotic diseases.
    Patent expiration dates:

    • March 26, 2017




  • Ziprasidone formulations
    Patent 6,150,366
    Issued: November 21, 2000
    Inventor(s): Arenson; Daniel R. & Busch; Frank Robert & Hausberger; Angela G. & Rasadi; Bijan
    Assignee(s): Pfizer Inc.
    Compositions comprising crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles having a mean particle size less than 85 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to treat psychoses such as schizophrenia.
    Patent expiration dates:

    • May 27, 2019
      ✓ 
      Drug product


    • May 27, 2019
      ✓ 
      Patent use: TREATENT OF PSYCHOSIS
      ✓ 
      Drug product




  • Inclusion complexes of aryl-heterocyclic salts
    Patent 6,232,304
    Issued: May 15, 2001
    Inventor(s): Kim; Yesook & Johnson; Kevin C. & Shanker; Ravi M.
    Assignee(s): Pfizer Inc.
    Compositions of matter comprising a pharmaceutically acceptable salt of an aryl-heterocyclic compound, such as ziprasidone, in a cyclodextrin. Preferred cyclodextrins are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrin inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in water at 40% w/v. A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate.
    Patent expiration dates:

    • April 1, 2017




  • Method of treating psychiatric conditions
    Patent 6,245,766
    Issued: June 12, 2001
    Inventor(s): Watsky; Eric J.
    Assignee(s): Pfizer Inc
    A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
    Patent expiration dates:

    • December 18, 2018
      ✓ 
      Patent use: TREATMENT OF BIPOLAR DISORDER




  • Inclusion complexes of aryl-heterocyclic salts
    Patent 6,399,777
    Issued: June 4, 2002
    Inventor(s): Yesook; Kim & Kevin C.; Johnson & Ravi M.; Shanker
    Assignee(s): Pfizer Inc.
    The esylate, mesylate, and tartrate salts of ziprasidone exhibit excellent solubilities in cyclodextrins.
    Patent expiration dates:

    • April 1, 2017




  • Ziprasidone suspension
    Patent 7,175,855
    Issued: February 13, 2007
    Inventor(s): Arenson; Daniel R. & Qi; Hong
    Assignee(s): Pfizer Inc.
    Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if setting occurs.
    Patent expiration dates:

    • May 18, 2020
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • November 20, 2012 - MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

See also...

  • Geodon Consumer Information (Drugs.com)
  • Geodon Consumer Information (Wolters Kluwer)
  • Geodon Capsules Consumer Information (Wolters Kluwer)
  • Geodon Consumer Information (Cerner Multum)
  • Geodon Advanced Consumer Information (Micromedex)
  • Geodon Intramuscular Advanced Consumer Information (Micromedex)
  • Geodon AHFS DI Monographs (ASHP)
  • Ziprasidone Consumer Information (Wolters Kluwer)
  • Ziprasidone Capsules Consumer Information (Wolters Kluwer)
  • Ziprasidone Consumer Information (Cerner Multum)
  • Ziprasidone Advanced Consumer Information (Micromedex)
  • Ziprasidone Intramuscular Advanced Consumer Information (Micromedex)
  • Ziprasidone AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)